Spinal Cord Stimulation in Heart Failure

Inclusion Criteria: * Patients has a left ventricular ejection fraction between 20% and 35% * Patient is in New York Heart Association Class III or in Ambulatory Class IV * Patient is receiving stable medical therapy for HF (\>90 days) at baseline * Patient has a left ventricular end diastolic diameter between 55 mm and 80 mm * Patient must be able and willing to provide written informed consent to participate in this study * Patient must be able and willing to comply with the required follow-up schedule Exclusion Criteria: * Patient currently has an implanted spinal cord stimulator or previously had an implanted upper thoracic spinal cord stimulator which is now explanted * Patient has polyneuropathy * Patient requires short-wave diathermy, microwave diathermy or therapeutic ultrasound diathermy * Patient has received a tissue/organ transplant (or is expected to have a tissue/organ transplant within the next 180 days) * Patient has persistent or permanent atrial fibrillation * Patient has chronic refractory angina or peripheral vascular pain * Patient has critical valvular heart disease that requires valve repair or replacement * Patient has had a myocardial infarction (MI) or cardiac revascularization procedure (percutaneous coronary intervention or coronary artery bypass graft) \<90 days at baseline or is expected to have this in the next 180 days * Patient is on IV inotropic therapy * Patient has active myocarditis or early postpartum cardiomyopathy * Patient has taken any of the following drugs within 30 days of enrollment: systemic corticosteroids, cytostatic and immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), DNA depleting or cytotoxic drugs * Patient is pregnant, or of childbearing potential and is not using adequate contraceptive methods, or nursing * Patient with a bleeding tendency (International Normalized Ratio \>1.2 and platelet count \<100 x10\^9 per liter) * Patient has a local infection at the implantable cardioverter-defibrillator (ICD) implant location or systemic infection * Patient has renal insufficiency (creatinine \>3.0 mg/dl) * Patient is participating in another clinical study * Patient is less than 20 years old * Patient's life's expectancy is less than 1 years as assessed by investigator